Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.

ABSTRACT:

Background/objectives

We examined the in vivo effects of successive treatments with the histone deacetylase (HDAC) inhibitor romidepsin in patients with cutaneous T-cell lymphoma (CTCL), using changes in gene expression in peripheral blood mononuclear cells (PBMCs).

Methods

Exploiting data from a highly responsive CTCL patient through 12 months of treatment, we identified a malignant cell predictor (MCP), a gene signature associated with the diminishing numbers of circulating malignant cells.

Results

The MCP was successfully validated in the patient's relapse sample 9 months after treatment was terminated and via an independent set of CTCL patient samples.

Conclusions

The MCP set of genes contained novel CTCL markers, including membrane-associated proteins not

SUBMITTER: Kossenkov AV 

PROVIDER: S-EPMC12293868 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature